In-Depth Examination Of 14 Analyst Recommendations For Apellis Pharmaceuticals
In-Depth Examination Of 14 Analyst Recommendations For Apellis Pharmaceuticals
對Apellis Pharmicals的14項分析師建議的深入研究
In the latest quarter, 14 analysts provided ratings for Apellis Pharmaceuticals (NASDAQ:APLS), showcasing a mix of bullish and bearish perspectives.
在最近一個季度中，14位分析師爲Apellis Pharmicals（納斯達克股票代碼：APLS）提供了評級，顯示了看漲和看跌的混合前景。
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
下表簡要介紹了他們最近的評級，展示了過去30天情緒的演變，並將其與前幾個月進行了比較。
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $77.14, with a high estimate of $92.00 and a low estimate of $52.00. This upward trend is apparent, with the current average reflecting a 12.2% increase from the previous average price target of $68.75.
分析師對12個月目標股價的評估提供了更多見解，顯示平均目標價爲77.14美元，最高估計爲92.00美元，低估值爲52.00美元。這種上升趨勢顯而易見，當前的平均價格較之前的68.75美元的平均目標股價上漲了12.2％。
Exploring Analyst Ratings: An In-Depth Overview
探索分析師評級：深入概述
An in-depth analysis...
對分析師...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。